Innovative Bispecific Nanobody Targeting CEACAM5 and FCGR3A for Next-Generation Cancer Therapies

VHH-P663 is a humanized nanobody-based bispecific construct designed to target both CEA cell adhesion molecule 5 (CEACAM5) and Fc gamma receptor IIIa (FCGR3A). Currently in the Biological Testing phase, VHH-P663 is engineered to leverage dual recognition of tumor antigens and immune cell activators for cancer treatment. This approach holds promise for enhancing anti-tumor immunity and improving therapeutic specificity. The construct integrates advanced molecular design to engage critical pathways implicated in cancer progression, offering a potential breakthrough modality for patients with high unmet medical needs.

Licensing Opportunity

VHH-P663 is available for out-licensing opportunities. We welcome discussions with partners interested in collaborative development and commercialization to accelerate this novel bispecific nanobody's path to clinical application in cancer immunotherapy.

Development Phase

Modality

VHH-P663 is a bispecific fusion construct composed of a single heavy chain variable domain antibody specific for CD16a, linked via a (G4S)3 peptide to an anti-CEA nanobody. Expressed in Escherichia coli BL21 cells, this modality harnesses the unique characteristics of nanobodies, including their small size, high stability, and superior tissue penetration. These properties facilitate efficient tumor targeting and access to challenging epitopes in complex tumor environments. For cancer treatment, the bispecific format enables simultaneous antigen recognition and immune cell engagement, maximizing therapeutic efficacy while potentially reducing off-target effects compared to conventional antibodies.

Target

CEACAM5 and FCGR3A are integral targets for cancer immunotherapy. CEACAM5 is a membrane-bound glycoprotein highly expressed on various cancer cells, playing a role in cell adhesion and tumor progression. FCGR3A is primarily found on immune effector cells such as natural killer (NK) cells, mediating antibody-dependent cell cytotoxicity. Targeting CEACAM5 allows for selective recognition of malignant cells, while engaging FCGR3A activates immune-mediated killing mechanisms. The combination of CEACAM5 and FCGR3A targeting in VHH-P663 creates a strategic advantage by uniting tumor-selective recognition with immune cell recruitment, promising a synergistic anti-cancer effect and differentiating its value in oncology drug development.

Mechanism of Action

VHH-P663 exerts its therapeutic effect by simultaneously binding CEACAM5 on cancer cells and FCGR3A on immune effector cells, such as NK cells. This dual mechanism enables the formation of an immunological synapse, facilitating targeted cytotoxicity against CEACAM5-expressing tumors. By acting as an NK-cell engager and modulating key signal transduction events, VHH-P663 enhances anti-tumor immune responses. The nanobody platform supports modular engineering, permitting rapid adaptation into other therapeutic formats like bispecifics or antibody-drug conjugates, expanding its utility across a spectrum of oncological indications.

Cancer

Cancer remains a leading cause of morbidity and mortality globally, affecting millions of people each year across diverse populations. While significant advances have been made through chemotherapy, radiation, immunotherapy, and targeted biologicals, many patients still experience limited response rates, disease recurrence, and adverse effects. Current treatments can lack selectivity, often impacting healthy cells alongside tumor tissue. There remains a pressing need for innovative, more targeted therapies that can improve outcomes and minimize toxicity. VHH-P663 addresses these challenges by bringing together precision recognition of cancer-associated markers and potent immune activation, representing a promising approach to fill existing therapeutic gaps and enhance patient care in oncology.